Overview

The purpose of this study is to find out if baricitinib can preserve beta-cell function in participants newly diagnosed with type 1 diabetes. Participation in the study will last about 60 weeks.

Eligibility

Inclusion Criteria:

• Have a new diagnosis of type 1 diabetes within 100 days prior to starting study intervention
• Have at least one diabetes-related autoantibody found at screening
• Show signs of remaining beta-cell function
  • stimulated (peak or 90 min) C-peptide ≥0.2 nmol/L (0.6 ng/mL) at screening
• Weigh at least 8 kilograms (kg) (18 pounds) at screening

Exclusion Criteria:

• Have any other type of diabetes including gestational
• Have uncontrolled high blood pressure
• Have had a heart attack, heart disease, stroke, or heart failure
• Have a history or high risk of venous thromboembolism, lymphoproliferative disease or malignancy
• Have a current or recent clinically serious medical condition or infection